• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trial Listings
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » MDS Completes Sale of Discovery, Preclinical Portion of CRO

MDS Completes Sale of Discovery, Preclinical Portion of CRO

March 9, 2010
CenterWatch Staff

MDS completed its sale of the discovery and preclinical business of MDS Pharma Services, the company’s contract research organization (CRO).  Under the terms of the deal, CRO Ricerca Biosciences of Concord, Ohio, acquired facilities in Bothell, Wash.; Lyon, France; and Taipei, Taiwan. Those facilities have 600 employees.

Ricerca is an early-stage CRO with capabilities in discovery and medicinal chemistry, API process chemistry, cGMP manufacturing and scale-up, and IND-enabling toxicology. MDS Pharma will add molecular profiling, pharmacology/DMPK and drug safety assessment to its list of services.

MDS is selling the remainder of its CRO business—the development and regulatory services consultancy as well as five early-stage facilities in Ireland, Nebraska, New Jersey, Arizona and Switzerland—to a new corporation primarily owned by private investment firms Bain Capital Ventures and SV Life Sciences. That sale is expected to close by the end of April. According to published reports, the total of both deals is approximately $45 million.

Neither deal includes the sale of MDS Pharma’s King of Prussia, Pa., executive office or its early clinical research and bioanalysis operations in Montreal, Quebec. The Pennsylvania office closed earlier this year, and the Montreal operations will be decommissioned over the next year with final close occurring in early 2011. Approximately 225 employees will be laid off as a result of the closures, while another 50 jobs will be eliminated from MDS Pharma Services’ other locations.

 

Upcoming Events

  • 25Apr

    Effective Root Cause Analysis and CAPA Investigations for Drugs, Devices and Clinical Trials

  • 26Apr

    FDA’s New Laws and Regulations: What Drug and Biologics Manufacturers Need to Know

  • 27Apr

    Califf’s FDA, 2023 and Beyond: Key Developments, Insights and Analysis

  • 17May

    2023 WCG Avoca Quality Consortium Summit

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • tablet

    Digital Intake Platforms Effective as Source of Trial Information, Survey Shows

  • Diversity-360x240.png

    Site Spotlight: EmVenio Research Takes to the Road to Promote Trial Diversity

  • Five Ws

    Consider the Five ‘W’s to Understand Potential Participants

  • QandA-360x240.png

    Perspectives from Smaller-Sized CROs: Q&A with Cheryle Evans

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing